Navigation Links
Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
Date:4/30/2013

CANTON, Mass., April 30, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a 1,021 patient survey, which consisted of patients with chronic pain currently on opioid medications. The survey was conducted by MedPanel, LLC, a specialized medical market insights firm. The objective of the survey was to understand patient attitudes and behaviors towards opioid medications and to assess patients' concerns related to currently available therapies for chronic pain. In addition, the survey assessed the percentage of patients with pain who have trouble swallowing pills and explored patient and physician awareness related to managing this important medical issue.     

Key findings from the survey highlight that opioid abuse and diversion are a significant concern for patients taking opioids for the treatment of chronic pain. Of all patients surveyed, 66% were concerned about social opioid abuse and 55% were concerned about becoming addicted. Furthermore, 36% of patients were concerned about someone taking their medication without their permission; 11% of patients had their medication stolen, most often from their home. When patients were asked, only 14% knew that there is an abuse-deterrent opioid in development. The majority of the patients surveyed (76%) indicated that they would be interested in switching to an analgesic medication similar to OxyContin®, but that is more abuse-deterrent.

The survey results confirmed that there is a significant unmet medical need for the treatment of patients with both chronic pain and dysphasia ("CPD"), a patient population consisting of 11 million people in the U.S. Of all patients surveyed, approximately 30% reported that they have trouble swallowing pills or do not like to swallow pills, yet only 19% of all patients had ever had their doctor ask them about their difficulties with swallowing. Furthermore, approximately 16% of patients who cannot or do not like to swallow pills either crush or grind their pills in order to facilitate swallowing. "Although all commercially available extended-release opioid products carry warnings related to product tampering (e.g., potential for fatal overdose if crushed), the majority of patients in the study (65%) were not aware that crushing or grinding changes the release characteristics of the medication, which has the potential to lead to a fatal overdose. This finding further demonstrates the need for an extended-release, abuse-deterrent opioid that can be sprinkled onto food or directly into the mouth or administered via enteral tube without compromising the ER properties of the analgesic," said Michael Heffernan , CEO of Collegium.   

"The patient survey results confirm that the oxycodone DETERx® formulation may provide a patient benefit not available with other oral extended-release opioids, especially those that have abuse-deterrent technologies that make the tablets harder to crush. We will be publishing the full results of this study in the coming weeks," said Michael Heffernan .

About DETERx® Technology

The DETERx® drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide abuse-deterrent properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastrostomy tube, while maintaining the extended-release properties of the product. DETERx® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. Oxycodone DETERx ® is the first of a number of product candidates using the DETERx® platform.

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx® oral drug delivery technology provides extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the Company's website at www.collegiumpharma.com.

About MedPanel, LLC

MedPanel, LLC, based in Cambridge, MA, provides market insights to leading corporate and financial clients in the life science industry and corporate financial transaction advisory to emerging life science companies. Its seasoned research staff understands the unique complexities and types of decisions that the MedPanel Insights group supports. Its domain expertise, global network of experts, and proven online methods all combine to help our clients make better decisions at every stage of the product life cycle, from inception of an innovative idea to post-launch and beyond. MedPanel's team of experienced transaction advisors provide strategic advice and direction in guiding clients in achieving its financing, M&A, and strategic partnering objectives.

Contact:

Michael Heffernan , President
Collegium Pharmaceutical, Inc.
781-713-3722
mheffernan@collegiumpharma.com


'/>"/>
SOURCE Collegium Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Collegium Pharmaceutical to Present at Piper Jaffrays 24th Annual Healthcare Conference
2. Collegium Pharmaceutical Announces Relocation to Massachusetts
3. Collegium Pharmaceuticals CEO to Present at the Cowen & Company 33rd Annual Health Care Conference in Boston on March 6, 2013
4. Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016  Zymo Research Corp. ... their new reference materials that help researchers obtain ... collection to analyses. The rapid growth of the ... researchers to have standard methods to improve the ... Biases inherently exist at every step of the ...
(Date:5/25/2016)... May 25, 2016  Granger Diagnostics today announced immediate ... wounds and infections. This test ensures discovery of ... viruses. The test requires only a simple swab of ... David G. Bostwick , MD, Chief Medical ... wound healing: "We are excited to make available, ...
(Date:5/25/2016)... , May 25, 2016 ... H1 2016"market research report that provides an overview ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University College of ... programs. , Answering to the increasing demand for curricular specializations, the Certificate in ... environmental and land use law. ,  , “The demand for lawyers with specific ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John Knox ... new model of care for living and healing, celebrated its grand opening, today. The ... a Real Home provided by Empowered Staff. , “This is an incredibly fulfilling time ...
(Date:5/26/2016)... ... ... MadgeTech will be showcasing its line of data logging products , ... MadgeTech headquarters. With products sold in more than 100 countries around the world, MadgeTech ... , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data loggers around ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising health care ... of Sun Health Senior Living (SHSL) may not share those same worries ... prescription copays for the year, while holding the line on increasing their contributions, including ...
(Date:5/26/2016)... ... 2016 , ... Leadership of Life Science Logistics (LSL), a ... earned its ISO 13485 certification, indicating the company’s quality control system for medical ... associated with ISO quality standard 13485. , BSI Group America, Inc., a ...
Breaking Medicine News(10 mins):